Capital Markets – Revival Or Reconfiguration?

While it is evident that the capital markets (especially in the life sciences space) are not anywhere near the feverish peaks of 2021, we are tracking signs of life that may be encouraging. What is exciting is that, as a result of macro trends, we might be seeing a shift in corporate development philosophy for late-stage capital raising among biotechs toward licensing as a public financing alternative.

Per J.P. Morgan’s Q1 2026 Biopharma and Venture Report, six biopharma Initial Public Offerings (IPOs) raised approximately $1.8 billion in Q1 2026 alone, already exceeding the total value of biotech IPOs completed during all of 2025. While that is encouraging in itself, it is important to note that this is more indicative of a narrow reopening of the public markets than a wider restoration of capital flow, and upon closer examination, an extension of trends we tracked last year. Nearly every life sciences company that has priced an IPO this year has met some combination of the